Changes in the level of clinical and renal parameters induced by transduction of Tat-fusion proteins for 16 weeks.

Diabetic OLETF rats were randomly divided into two groups, a Tat-GFP treatment group and a Tat-MT-Tat-SOD combination treatment group. The former were injected every 3 days with 3 mg/kg of Tat-GFP, and the latter with 3 mg/kg of Tat-MT and 3 mg/kg of Tat-SOD. The fusion protein treatment continued for 16 weeks. LETO rats were used as histological controls. Urinary protein levels were determined by the Bradford method and microalbumin levels were measured with a microalbumin quantitation ELISA kit (Bethyl Laboratories, Montgomery, TX).
Values are expressed as means±SEM.
*p<0.05 vs. OLETF
**p<0.01 vs. OLETF
†p<0.05 vs. OLETF+Tat-GFP
‡ p<0.01 vs. OLETF+Tat-GFP by repeated measures of ANOVA.
#p<0.05 vs. OLETF
##p<0.01 vs. OLETF
$p<0.05 vs. OLETF+Tat-GFP
$$p<0.01 vs. OLETF+Tat-GFP by one-way ANOVA.
Abbreviations; TGFP: Tat-GFP, TMTS: Tat-MT-Tat-SOD combination.
Changes in the level of clinical and renal parameters induced by transduction of Tat-fusion proteins for 16 weeks.